Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt

Placebo-controlled Study of Varenicline Effects on Nicotine Withdrawal Followed by a Test of Smoking Topography, Reward, and Reinforcement

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00571805

Acronym

VarenSmoke

Enrollment

Registered

2007-12-12

Start date

2007-09-30

Completion date

Unknown

Last updated

2015-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence

Keywords

cigarette, craving, reward

Brief summary

Study of varenicline 2.0 mg/day treatment for 2 weeks with smoking test done in laboratory on Day 8 and a 1 week quit attempt from Day 8-14.

Interventions

DRUGvarencline

2.0 mg/day varencline (1.0 mg BID)

DRUGplacebo

matching placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* At least 10 cigarettes/day * Interest in quitting smoking * Willgness to comply with overnight smoking abbstiennce period followed by lab smoking test

Exclusion criteria

* Pregnancy * Axis I psychiatric disorder which require treatment with psychoactive medication and would make study compliance difficult. * Clinically significant medical condition in opinion of study clinician * Drug or alcohol dependence inlast 12 months * Use of other smoking cessation medications ot treatment progams in last 2 months

Design outcomes

Primary

Measure	Time frame
Smoking reward	laboratory test

Secondary

Measure	Time frame
1 week abstinence induced craving and reward	Day 8, 9, 11 and 14 questionaires

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026